Anlegen für die lange Frist: Die gedruckte Sonderausgabe von The Market. 32 geballte Seiten Analyse, Inspiration und Interviews für den langfristigen Erfolg in der Geldanlage. Heute in der NZZ und hier zum Gratis-Download 👇 themarket.ch/hinter-der-hea…

BREAKING NEWS 💥💥💥The bank in England has fallen

Here are the 4 key measures just agreed by EU energy ministers🇪🇺

Season start of gas winter. Change of regulatory framework. Stop of flows. Coincidence? Sure. Christoph Offenhäuser Mark Dittli

Shocking moment of truth on Bloomberg when Professor Jeffrey Sachs says he believes the US was behind the Nord Stream pipelines destruction. The reporters start to lose it, of course.

For all professional commodity traders and investors: Forecasting flat price using flows, fundamentals and macro. Highly recommended! Count me in. itsnotascience.com

Pertinent!

Unser Risk on/off Indikator kratzt wieder an einem Sell Signal. Let's see. courtesy of ADV

Sometimes it's very valuable to live in Bern. A rock solid hint from an insider: Federal Council & FINMA to meet Saturday and especially Sunday. Topic: Top (CS)ecret Oh oh....?

Brilliant marketing or what? Christoph Offenhäuser Matthias Geissbühler, CFA, CMT Berner Kantonalbank AG

Intel before Financial Times ?

Ah come on, stop whining.

Getting our crew started for the day!

Wow! TotalEnergies CEO challenging Engie CEO to say true cost of offshore wind! #OOTT #Gas

THIS is why you keep trading through the rough times Caught the bottom and top for FOMC Giving away $1,500 to three people $500 each RT and LIKE ❤️ - Must be following $SPY $SPX $QQQ pic.x.com/Z1k6VSDchP

🔸A Recession Is No Longer the Consensus Economists are turning optimistic on the U.S. economy. They now think it will skirt a recession, the Federal Reserve is done raising interest rates and inflation will continue to ease. In the latest quarterly survey by The Wall Street

Wow! Hedgeye

Capricor is very pleased to announce that we have completed the submission of our Biologics License Application (BLA) to the U.S. FDA for deramiocel for the treatment of Duchenne muscular dystrophy. We look forward to working with the FDA throughout the review process to support

where prosperity?

Exceptionally poor media coverage these days across the board including The Wall Street Journal.